Wednesday, 28 October 2026 Every NSE & BSE announcement, by company
ALFA Filings Every announcement, straight from the exchange
Price Movement Clarification

Dr. Reddy's Laboratories Price Movement Clarification

Dr. Reddy's Laboratories clarified a news report regarding its Semaglutide Injection. The company confirmed it has not yet received a 'Notice of Compliance' from Health Canada but did receive 'Drug Identification Numbers' (DINs) on April 22, 2026. The company continues to engage with regulatory authorities for Canadian market approval.

Source

BSE filing, NSE: DRREDDY. Summary written from the filing by ALFA Finder's alert engine.

Read the filing ↗

Dr. Reddy's Laboratories Ltd: key numbers

Share price
₹1,335.40
Market cap
₹1,11,463 Cr
Revenue (annual)
₹33,700 Cr
Net profit (annual)
₹4,196 Cr
P/E (TTM)
39.8×Sector 46.1×
Promoter holding
26.63%-0.01% QoQ
FII holding
20.30%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

More from Dr. Reddy's Laboratories Ltd

All →

Other price movement clarification announcements

All →